Dr Devinder Chauhan will showcase Macuject’s recent advances in AI and CDS at the Ophthalmology Futures Forum retina meeting on 30th Sept 2020.
The Futures Forum meeting has been highlighting the latest innovations in ophthalmology since 2012. This year it will be held as a virtual event, with scientists, physicians, regulators, reimbursement specialists, corporate leaders, and investors from across Europe, the Americas, and Asia-Pacific.
Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on new technology, entrepreneurial ventures, market access and other aspects of commercialisation in the ophthalmic healthcare sector. They cover all aspects of global innovation in ophthalmic devices, diagnostics and pharmaceuticals.
The meeting features round-table discussions, presentation of latest innovations in the field, and one-on-one interviews This year, these interviews will be with Dr Wiley Chambers of the FDA and Marie-France Tschudin, president of Novartis Pharmaceuticals.
Over the last 12 months Macuject has significantly advanced its AI and CDS platform, and is now actively involved in clinical testing.
Dr Chauhan’s presentation will address the global problem of undertreatment with intravitreal injections, and how Macuject can assist by increasing the capacity of doctors who currently perform anti-VEGF injections, and enable non-retinal specialists to deliver these treatments with increased clinical confidence.
He will also highlight the unprecedented data insights Macuject can generate for doctors and Pharma alike.
Macuject has signed several agreements with several technical and pharma partners. At the Ophthalmology Futures Forum we seek to connect with new commercial partners, and also investors interested to join our next phase of product refinement, regulatory approval and market launch.
We hope that it will lead to partnerships, collaboration and investment.
For more information about OFF, please visit: https://www.ophthalmology-futures.com/forums/#tabs-515)